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Essentials
• The pathogenesis of immune thrombocytopenia (ITP) has not been fully clarified.
• We analyzed the role of anti-avb3 autoantibody in the pathogenesis of ITP in patients.
• Anti-avb3 autoantibody impeded megakaryocyte migration and adhesion to the vascular niche.
• Anti-a v b 3 autoantibody potentially contributes to the pathogenesis of refractory ITP.
Summary. Background: The pathogenesis of immune thrombocytopenia (ITP) has not been fully clarified. Anti-avb3 integrin autoantibody is detected in chronic ITP patients, but its contribution to ITP is still unclear. Objectives: To clarify the potential role of antiavb3 integrin autoantibody in chronic ITP and the related mechanism. Methods: Relationship between levels of antiavb3 autoantibody and platelets in chronic ITP patients was evaluated. The influence of anti-avb3 antibody on megakaryocyte (MK) survival, differentiation, migration and adhesion was assessed, and the associated signal pathways were investigated. Platelet recovery and MKs' distribution were observed in an ITP mouse model pretreated with different antibodies. Result: In this study, we
showed that the anti-avb3 autoantibody usually coexists with anti-aIIbb3 autoantibody in chronic ITP patients, and patients with both autoantibodies have lower platelets. In in vitro studies, we showed that the anti-avb3 antibody had no significant effect on the survival and proliferation of MKs, whereas it decreased formations of proplatelet significantly. Anti-avb3 antibody impeded stromal cell derived facor-1 alpha (SDF-1a)-mediated migration and inhibited the phosphorylation of protein kinase B. Anti-avb3 antibody significantly inhibited MKs' adhesion to endothelial cells and Fibrogen. The phosphorylation of focal adhesion kinase and proto-oncogene tyrosine-protein kinase Src induced by adhesion was inhibited when MKs were pretreated with anti-avb3 antibody. In in vivo studies, we showed that injection with anti-a v antibody delayed platelet recovery in a mouse model of ITP. Conclusions: These findings demonstrate
Introduction
Immune thrombocytopenia (ITP) is an acquired autoimmune disorder characterized by a severe decrease in the number of circulating platelets [1] . The incidence of newly diagnosed ITP patients ranges from 1.6 to 3.9 per 100 000 persons per year [2, 3] , and 11-28% of these patients may experience chronic/refractory ITP [4, 5] . Although few ITP patients eventually die due to severe thrombocytopenia, most of these individuals suffer greatly from bleeding and complications of therapy.
The pathogenesis of ITP has not been thoroughly elucidated to date. Glycoprotein-specific immunoglobulin G (GP-specific IgG) is a key player in ITP pathogenesis [1, 5, 6] . GP-specific IgG, such as autoantibody against glycoprotein (GP) IIb/IIIa (a IIb b 3, CD41/61), also called anti-a IIb b 3 antibody, can bind platelet membrane integrin a IIb b 3 antigens and result in platelet destruction in the reticuloendothelial system. Anti-a IIb b 3 antibody also binds megakaryocyte (MK) membrane antigens and decreases MK proliferation, thereby affecting platelet production [6] [7] [8] [9] . However, the inhibitory effect of anti-a IIb b 3 antibody on MKs cannot fully explain why there is an evident impediment of MK maturation but not a significant decrease in the number of MKs in ITP patients [10] . Integrin a v b 3 , which is broadly expressed on cancer and normal cells [11] [12] [13] , is also a special platelet integrin antigen for GP-specific IgG. Anti-a v b 3 autoantibody was detected in chronic ITP patients [14, 15] , whereas its role in ITP is unknown.
The in vivo thrombocytopoiesis process is accompanied by MK migration from osteoblast niche to vascular niche in bone marrow [16, 17] . Proplatelets are formed when MKs reach the blood vessel sinus, and the cells subsequently adhere to vascular endothelial cells (ECs) and place their pseudopodia into the vascular cavity to produce platelets through blood flow erosion. Previous studies, including the present study, have shown that promoting MK migration and adhesion can facilitate proplatelet formation and platelet production [18, 19] . The integrin a v b 3 is involved in several physiopathological processes via regulating the adhesion and migration of targeted cells [20, 21] . However, whether integrin a v b 3 has a regulatory effect on MK migration and adhesion during thrombocytopoiesis is unclear.
In the present study, we detected the levels of anti-a v b 3 autoantibody in chronic ITP patients and investigated its role in the pathogenesis of ITP. These findings reveal that anti-a v b 3 autoantibody may aggravate thrombocytopenia in ITP patients by inhibiting the migration and adhesion of MKs to the vascular niche.
Materials and methods

Patients and controls
A total of 103 venous blood and bone marrow (BM) biopsies were collected from chronic ITP patients whose platelets were lower than 30 9 10 9 L À1 (71 women and 32 men, age range 18-77 years, median age 37 years). All patients were administered at least one course of therapy and followed-up for at least 12 months (Table 1) . The chronic ITP diagnosis was determined according to established criteria [22] . Twenty-one peripheral blood and BM samples were collected from healthy donors as controls (13 women and eight men, age range 18-63 years, median age 35 years, platelet counts range 142-275 9 10 9 L
À1
).
The present study was approved by the Medical Ethical Committee of the Third Military Medical University and conducted in accordance with the Declaration of Helsinki.
Platelet isolation and elution of platelet-associated immunoglobulins
Samples of 5 mL of EDTA-anticoagulated peripheral blood obtained from patients or normal donors was first centrifuged (100 g for 15 min), the PRP (platelet-rich plasma) was centrifuged (12 000 g for 10 min), and the centrifuged deposited platelets were then washed six times with 0.05 mol L À1 isotonic citrate buffer. The washed platelets were centrifuged and resuspended in eluent solution, and the resuspended cells were subsequently centrifuged (12 000 g for 10 min) twice. The eluates were later collected and stored at À80°C before the detection of platelet-associated antibodies. 
Migration analysis
Migration was assessed by using 24-well Millicell Ò cell culture inserts (8 lm PET, Millipore, Burlington, MA, USA). The starved HUCB CD34 + cell-derived MKs were pretreated with LM609 (10 lg mL À1 ) or different plasma samples at 37°C for 4 h and later placed into the upper chamber, and the bottom chamber contained serum-free medium with SDF-1(stromal cell derived facor-1 alpha) or precoated with ECs. After a 5-h incubation at 37°C, the cells that migrated through pores in the Transwell were fixed with 4% paraformaldehyde, stained with 0.2% crystal violet (Beyotime) and subsequently counted.
Western blotting
HUCB CD34
+ cell-derived MKs were suspended at 5 9 10 6 cells/well, seeded onto 12-well plates and incubated with LM609 or/and SDF-1 at 37°C for 1 h. Next, the cells were added to the Fg-coated plates and collected at the specified time-points. The cell extracts were loaded on a sodium dodecyl sulfate polyacrylamide gel and transferred to a semidry transfer system (Bio-Rad, Hercules, CA, USA). After that step, the proteins were probed with primary antibodies against protein kinase B (p-AKT), p-focal adhesion kinase (FAK), proto-oncogene tyrosine-protein kinase Src (p-SRC), AKT, FAK, SRC (Cell Signaling Technology, Danvers, MA, USA), GAPDH (Beyotime) and appropriate HRP-labeled secondary antibodies. The membranes were briefly incubated with the ECL detection reagent (Amersham) and exposed to the Molecular Imager Ò ChemiDoc TM XRS+ with the Image Lab TM software (BIO-RAD).
Immunofluorescence staining HUCB CD34 + cell-derived MKs were incubated with or without LM609 (10 lg mL À1 ) for 4 h, and the cells were co-cultured with ECs overnight. After that step, the cells were fixed and stained with the antibodies against p-FAK and p-SRC and appropriate secondary antibody. The cells were washed and visualized under laser confocal microscopy (Carl Zeiss, Oberkochen, Germany), and the fluorescence intensity was quantified with the NIH ImageJ.
Proplatelet formation assay
Proplatelet formation assay was performed as previously described [18, 19] . CD34 + cell-derived MKs were treated with or without LM609 (10 lg mL À1 ) for 4 h and seeded onto Fg-coated (100 lg mL
À1
) plates at a density of 5 9 10 5 cells mL
. After 24 h, the cells were fixed with 4% paraformaldehyde, permeabilized with 0.25% Triton X-100 and then stained with 4'6-diamidino-2-phenylindole (DAPI) and the anti-b1 tubulin antibody. Finally, the cells were analyzed with a laser confocal microscope.
ITP model mouse experiment
The present study was approved by the Animal Care Committee of the Third Military Medical University (Chongqing, China). Male BALB/c mice (8-10 weeks of age) were purchased from the Institute of Zoology (Chinese Academy of Sciences, China). The mice were intraperitoneally injected with saline, 200 lg kg À1 of antia IIb antibody (MWReg30, a rat IgG antibody against mouse CD41 (a IIb ), Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA), anti-a IIb antibody combined with 400 lg kg À1 of anti-a v antibody (RMV-7, a rat IgG antibody against mouse CD51(a v ), Biolegend) and anti-b3 antibody(2C9.G2, LEAF TM Purified anti-mouse/rat CD61 Antibody, Biolegend)daily for 7 days. Blood samples were collected from the tail veins of the mice and the cells were counted.
Hematological parameter test
Peripheral blood samples were collected in anticoagulant tube with 1% EDTA solution on the indicated days. The platelets in the blood samples were automatically quantified with a hematology analyzer (Sysmex XT1800i/2000IV, Kobe, Hyogo, Japan).
Statistical analysis
The experimental data in the present study are results from at least three independent experiments and represent the means AE SD. Correlation analysis was performed with Spearman's rank correlation. Statistical analysis was performed by a two-tailed Student's t-test for data involving two groups, and comparisons among multiple groups were performed with one-way analysis of variance (ANOVA) followed by Tukey's post hoc test. P < 0.05 was considered to be statistically significant.
Results
The expression of anti-a v b 3 autoantibody in chronic ITP patients and the associated platelet level and MKs' location All plasma samples were analyzed by MACE to detect anti-a v b 3 and anti-a IIb b 3 autoantibodies ( Table 1) . The total positive rates of anti-a IIb b 3 autoantibody and antia v b 3 autoantibody detected were 35.92% (n = 37) and 30.10% (n = 31), respectively. Among 31 anti-a v b 3 -positive patients, 29 patients were also anti-a IIb b 3 positive. As shown in Fig. 1(A) , the platelet levels in patients positive for both anti-a IIb b 3 and anti-a v b 3 autoantibodies were slightly lower than those in patients with only anti-a IIb b 3 autoantibody.
Additionally, we examined the pathological changes in the BM biopsies and observed no significant decrease in the total number of MKs in chronic ITP patients. Interestingly, compared with the anti-a v b 3 autoantibody-positive group, more megakaryocytes were predominantly located in the vicinity of sinusoidal BMECs in the antia v b 3 autoantibody-negative group. The number of MKs that located in sinusoids (MKs that attached to sinusoids or near sinusoids within 100 lm distance between MKs and sinusoids) were 5.47 AE 1.46, 4.73 AE 1.67 and 2.4 AE 1.59 in the section view of the control group, antiavb3(À) group and anti-avb3(+) group separately. A difference was found between the anti-avb3(+) group and the control group (P < 0.05), and also between the antiavb3(+) group and the anti-avb3(À) group(P < 0.05) (Fig. 1B, Figure S1 ). ), and CD41/CD42b expression was detected at different timepoints (d7/d10/d13). As shown in Fig. 2(A, B) , the differentiation of MKs was not influenced by anti-a v b 3 antibody. The results of trypan blue analysis showed that, in contrast to the cell death-inducing effect of anti-a IIb b 3 antibody on MKs, LM609 did not affect the survival of MKs (Fig. 2C, D) . Moreover, the viability assay demonstrated that the anti-a IIb b 3 antibody significantly reduced the proliferation of the megakaroblastic cell line (M07e), whereas the anti-a v b 3 antibody had no significant effect on the proliferation of M07e cells (Fig. 2E, F) .
Next, we investigated whether the anti-a v b 3 antibody has an influence on proplatelet formation. After culturing with rhTPO (20 ng mL À1 ) for 13 days, HUCB CD34 + cell-derived MKs were reseeded onto Fg-preconditioned 24-well plates and treated with LM609 for 24 h. Threadlike cytoplasmic extensions with bead-like nubs were defined as typical proplatelet formations under an inverted microscope. Compared with the control group, proplatelet formations significantly decreased in LM609-treated MKs (Fig. 2G, H) . The reduced proplatelet formation in MKs after anti-a v b 3 antibody treatment was further confirmed by immunofluorescent anti-tubulin staining (Fig. 2I ).
Anti-a v b 3 antibody inhibits MK migration via suppressing AKT activation
The migration of MKs from the osteoblast niche to the vascular niche is a key event in thrombocytopoiesis in vivo, and SDF-1 plays a crucial role in regulating MK migration. Therefore, we subsequently investigated whether anti-a v b 3 antibody affects SDF-1-induced MK migration using a Transwell system. As shown in Fig. 3(A, C) , SDF-1 displayed a strong ability to promote MK migration, and LM609 could dramatically decrease the migration of MKs induced by SDF-1. Moreover, compared with the plasma from normal control and antia v b 3 autoantibody-negative patients, the anti-a v b 3 autoantibody-positive group displayed weaker ability to induce MK migration (Fig. 3B, D) . Further investigations revealed that the phosphorylation of AKT markedly increased in MKs after SDF-1 stimulation (Fig. 3E, F) , whereas LM609 could evidently inhibit AKT activation (Fig. 3G, H ). These data demonstrate that the anti-a v b 3 antibody functions as a potent inhibitor of MK migration, probably by suppressing AKT signaling.
Anti-a v b 3 antibody inhibits MK adhesion via blocking the phosphorylation of FAK and SRC
Adhesion to bone marrow stroma is crucial for MK migration and is also a key event in thrombocytopoiesis. Next, we detected whether the anti-a v b 3 antibody has an impact on MK adhesion to Fg. HUCB CD34 + cellderived MKs were incubated with LM609 or the plasma from chronic ITP patients for 4 h before transferring to Fg-preconditioned plates. Compared with control groups, pretreatment with LM609 and anti-a v b 3 autoantibodypositive plasma markedly reduced the adhesion of MKs to the plates ( Figure S2 ). To further uncover the mechanism underlying the inhibitory effect of anti-a v b 3 antibody on MK adhesion, we detected the changes of related signal pathways. Both FAK and SRC were rapidly and strongly phosphorylated in MKs after contact with Fg (Fig. 4A, B) , whereas pretreatment with LM609 inhibited the phosphorylation of both FAK and SRC (Fig. 4C, D) . These data indicate that the anti-a v b 3 antibody has the property to inhibit MK adhesion by blocking the phosphorylation of FAK and SRC.
Anti-a v b 3 antibody impedes MK migration and adhesion to vascular endothelial cells
To determine the pathological activity of the anti-a v b 3 antibody, we investigated its influence on the interaction between MKs and vascular endothelial cells (ECs). As shown in Fig. 5(A, B) , an evident migration of MKs toward ECs was observed in the Transwell system, whereas LM609 significantly inhibited the migration of MKs toward ECs. In addition, LM609 also significantly inhibited MKs' adhesion to ECs (Fig. 5C, D) . Immunofluorescence staining revealed the strong expression of p-FAK and p-SRC in MKs co-cultured with ECs, whereas LM609 pretreatment could decrease the expression levels of p-FAK and p-SRC (Fig. 5E-H ). These data demonstrate that anti-a v b 3 antibody can impede MKs' migration and adhesion to ECs, which may result in the delayed release of platelets into the vascular sinus.
Anti-a v antibody injection delays platelet recovery in the anti-a IIb antibody-induced ITP mouse model Finally, we evaluated the pathological significance of anti-a v b 3 antibody in vivo. An ITP mouse model was generated by injection with the anti-a IIb antibody (WMReg30) for 7 days (Fig. 6A) , as previously described [23, 24] . Similarly, because a v integrin is the main domain of a v b 3 and targeting a v reduces the migration ability of certain cells [12, 13, 25] , anti-a v (CD51) antibody was applied in the in vivo experiment. The platelet levels in the mice injected with anti-a IIb and anti-a v /a IIb antibodies remarkably decreased, whereas the anti-b 3 slowly declined (Fig. 6B) . Notably, a longer duration of thrombocytopenia and a slower recovery of the platelet levels were found in mice treated with anti-a v /anti-a IIb antibodies compared with those in the anti-a IIb antibody alone or anti-b3 treated mice (Fig. 6B) . H&E staining showed that there was no difference in the numbers of MKs among the groups at day 7. However, MKs which located in the vicinity of sinusoidal BMECs in control and anti-aIIb group, were more than in the anti-av/anti-aIIb and anti-b3 groups; the number of MKs which located in sinusoids were 7.87 AE 1.92, 7.33 AE 1.50, 3.60 AE 1.55 and 3.20 AE 1.61 in the section view of the control group, anti-aIIb group, anti-aIIb+anti-av group and anti-b3 group separately (Fig. 6C, Figure S3 ), suggesting that the anti-a v b 3 antibody impedes the migration of MKs into the vascular sinus, which may contribute to the delay of platelet recovery.
Discussion
GP-specific IgGs, such as a IIb b 3 autoantibodies, have been widely recognized and thought to be the primary causes of ITP [1, 6, 8] . However, the pathological significance of the anti-a v b 3 autoantibody in ITP patients has not been thoroughly elucidated to date. In this study, we demonstrated that the anti-a v b 3 autoantibody aggravates thrombocytopenia by impeding MK migration and Integrin a v b 3 has been found to be expressed in MKs [26] , and the anti-a v b 3 autoantibody has been reported in chronic ITP patients [15, 27] . In the present study, we determined a rate (28.16%) of anti-a v b 3 autoantibody in chronic ITP patients. Interestingly, we observed that antia v b 3 (+) patients had slightly lower platelet counts and fewer MKs located in sinusoidal BMECs compared with anti-a v b 3 (À) patients, indicating that the anti-a v b 3 autoantibody may be involved in the pathogenesis of thrombocytopenia. The anti-a IIb b 3 autoantibody not only destroys platelets but also inhibits the survival and proliferation of MKs [28] [29] [30] [31] . Accordingly, we performed a series of experiments to uncover the distinct effect of the anti-a v b 3 autoantibody on MKs. These preliminary data demonstrated that the anti-a v b 3 autoantibody had no The migration of MKs is crucial for the processing of thrombocytopoiesis in vivo [16, 19, 32] . SDF-1, which is mainly produced by osteoblasts and ECs in the bone marrow, is regarded as the key regulator for cell migration [33, 34] . Previous studies have demonstrated that administration of SDF-1 can promote thrombocytopoiesis without changing the numbers of MKs in the bone marrow, the process might be associated with activation of the PI3K/AKT pathway [35, 36] , and SDF-1 induced a v or b 3 integrin expression on targeted cells [37] [38] [39] . In the present study, we showed that SDF-1 stimulated the expression of integrin a v b3 on MKs ( Figure S4 ), and the anti- correlatively fewer MKs locating in the vascular niche in an ITP mouse model; a similar phenomenon was also found in the bone marrow biopsy of anti-a v b3(+) ITP patients. These findings may indicate that integrin a v b 3 may regulate migration of MKs through the PI3K/AKT pathway, and the anti-a v b 3 autoantibody may impede MK maturation and platelet production through inhibiting MK migration toward a vascular niche.
At the late stage of thrombocytopoiesis, mature MKs attach to vascular ECs and the extracellular matrix (ECM) around the vascular sinus where the platelets are produced and released. In the present study, we observed that MKs naturally adhered to ECs when they were cocultured, whereras the anti-a v b 3 antibody could significantly inhibit MK adhesion to ECs (Fig. 5A and C) . Moreover, evident proplatelet formation and platelet production were observed when MKs were co-cultured with ECs, whereas these phenomena became weak in the presence of the anti-a v b 3 antibody (Fig. 5) . These results reveal that integrin a v b 3 may be involved in the interaction between MKs and vascular ECs, which is crucial for the terminal differentiation of MKs. As reported, the adhesion of MKs to the ECM and stromal cells mediated by integrins is associated with the activation of FAK and SRC signaling pathways [40] [41] [42] , as the C-terminus of FAK can direct FAK to the focal adhesion complex to promote its co-localization with integrins and provide the binding sites for Src homology 3 (SH3) domain-containing proteins. The phosphorylation of FAK and SRC induced by integrins will lead to the movement of the cytoskeleton and adhesion to the ECM. In this study, we observed that FAK and SRC were rapidly phosphorylated when MKs made contact with Fg or ECs, whereas the phosphorylation of FAK and SRC in MKs could be significantly inhibited by the anti-a v b 3 antibody. These findings further confirm the impact of the anti-a v b 3 antibody on the interaction between MKs and ECs. In fact, the adhesion of MKs to Fg, the main component of the EC matrix, is conducive to proplatelet formation [40, 43, 44] . In the present study, we also found that antia v b 3 antibody pretreatment could significantly inhibit the proplatelet formation in MKs cultured on Fg-coated plates, which was consistent with the result of a previous study showing that the anti-a v b 3 antibody could markedly decrease proplatelet formation in vitro [45] . Thus, the present study could also provide support for the view that impaired proplatelet formation contributes to decreased platelet count in ITP patients [45, 46] .
In animal experiments, mice were treated with the antia IIb antibody with or without injection of the anti-a v antibody. As previously reported [23, 24] , anti-a IIb antibody treatment alone decreased the platelet counts to a very low level. In this study, we showed that a longer duration of thrombocytopenia and slower recovery of the platelet level were observed in anti-a IIb /anti-a v antibody-treated mice. This phenomenon can be interpreted by the in vitro findings that the anti-a v b 3 antibody impedes the migration and adhesion of MKs, although it does not directly destroy the platelets. In other words, the existence of the anti-a v b 3 autoantibody may aggravate thrombocytopenia. Santoso et al. [47] reported three anti-b 3 antibodies (anti-b 3, antia v b 3 and anti-a IIb b 3 ) in fetal/neonatal autoimmune thrombocytopenia. In the present study, we also treated mice with the anti-b3 antibody. The results showed that mice treated with anti-b3 showed slower reduction of platelets compared with the anti-a v /anti-a IIb or anti-a IIb group. This phenomenon might be explained by the different affinity of the integrin isotype [48] , whereas few studies have reported 'single chain' antibodies, such as the anti-b3 autoantibody in ITP patients, and the influence of the anti-b3 antibody needs to be further studied.
Despite the promising findings, there are several limitations to the present study. First, the human materials used in the present study were patient serums instead of purified IgG. Although we obtained positive results from anti-a v b 3 (+) serum, we cannot exclude the potential influence of other proteins or factors in the serum. Second, platelet-associated autoantibodies in ITP patients are complicated and varied, and besides the two autoantibodies described in this report, other autoantibodies, such as anti-GPIb/IX, also play important roles in the pathogenesis of ITP. The relationship between the different autoantibodies needs further investigation. Taken together, these data partially demonstrate that integrin avb3 may be involved in the regulation of thrombocytopoiesis, and the anti-avb3 autoantibody is likely to be synergistic with the anti-aIIbb 3 Science Foundation (2014T70976), the Natural Science Foundation of Chongqing (cstc2013jcyjA10119), and the Special Financial Grant from Chongqing Postdoctoral Science Foundation (Xm201339).
Disclosure of Conflict of Interests
The authors state that they have no conflict of interest.
Supporting Information
Additional supporting information may be found online in the Supporting Information section at the end of the article: Fig. S1 . Number of MKs which located in sinusoids of human bone marrow biopsy. 
